Newest Treatment for Acute COVID-19
For high-risk adults with acute COVID-19 within 5 days of symptom onset, use nirmatrelvir-ritonavir (Paxlovid) as first-line therapy, with molnupiravir as an alternative when nirmatrelvir-ritonavir is contraindicated or unavailable. 1
Current Standard of Care
The 2024 American College of Physicians guidelines provide clear direction for outpatient COVID-19 treatment 1:
First-Line Recommendations
Nirmatrelvir-ritonavir remains the preferred oral antiviral for symptomatic patients with confirmed mild-to-moderate COVID-19 who:
- Are within 5 days of symptom onset
- Have high risk for progression to severe disease
- Can tolerate the drug-drug interactions with ritonavir
Evidence shows nirmatrelvir-ritonavir reduces:
- All-cause mortality (4 studies showing reduction)
- COVID-19 mortality (1 RCT)
- Hospital admissions (1 study showing reduction)
- Serious adverse events (2 studies showing reduction)
Second-Line Alternative
Molnupiravir serves as an alternative when nirmatrelvir-ritonavir cannot be used, with evidence demonstrating:
- Reduction in all-cause mortality (3 studies)
- Reduction in time to recovery (1 study)
- Similar safety profile to placebo
Emerging Treatments (Not Yet Standard)
Simnotrelvir
A newer 3-chymotrypsin-like protease inhibitor showed promise in a 2024 phase 2-3 trial 2:
- Shortened time to symptom resolution by 35.8 hours versus placebo (P=0.006)
- Greater viral load reduction at day 5
- Administered as 750 mg simnotrelvir plus 100 mg ritonavir twice daily for 5 days
- However, this is not yet approved or recommended in guidelines
VV116
A remdesivir analog with oral bioavailability demonstrated noninferiority to nirmatrelvir-ritonavir 3:
- Similar time to clinical recovery (4 days vs 5 days)
- Fewer adverse events (67.4% vs 77.3%)
- Not yet incorporated into standard guidelines
Obeldesivir
A 2026 study showed this nucleoside analog was underpowered and did not improve hospitalization or death 4, making it not clinically useful despite viral load reductions.
Critical Caveats
Important Limitation for Vaccinated Populations
A major 2026 open-label trial (PANORAMIC/CanTreatCOVID) found nirmatrelvir-ritonavir did NOT reduce hospitalization or death in vaccinated higher-risk adults 5. This challenges the benefit in vaccinated populations, though the open-label design and low event rates limit interpretation. The guideline recommendations predate this finding.
What NOT to Use
- Ivermectin: Explicitly not recommended 1
- Sotrovimab: Not recommended due to lack of efficacy against current variants 1, 6
Practical Algorithm
For acute COVID-19 in high-risk adults:
Confirm eligibility: Symptoms ≤5 days, mild-to-moderate disease, high-risk features (age ≥50, immunocompromised, chronic conditions)
Check for drug interactions: Review all medications for CYP3A4 interactions with ritonavir
If no contraindications → Prescribe nirmatrelvir 300 mg/ritonavir 100 mg twice daily × 5 days
If significant drug interactions or contraindications → Prescribe molnupiravir 800 mg twice daily × 5 days
Monitor for adverse events: Dysgeusia is significantly more common with nirmatrelvir-ritonavir 7
The evidence base strongly supports these two agents, with nirmatrelvir-ritonavir showing the most robust mortality and hospitalization benefits in the original high-risk, unvaccinated populations 1. While newer agents like simnotrelvir show promise, they have not yet been validated in guidelines or approved for widespread use.